ONCAlert | 2018 ASCO Annual Meeting

PFS and Safety With Nivolumab Plus Ipilimumab in Advanced Melanoma

Marc Ernstoff, MD
Published Online: 6:43 PM, Fri July 17, 2015

Marc Ernstoff, MD, director of melanoma, Cleveland Clinic, discusses progression-free survival (PFS) and safety in patients with advanced melanoma receiving nivolumab combined with ipilimumab.
Ernstoff describes the 2:1 randomization of this phase II study. He mentions that management of toxicities is still in development, but they immediately stop treatment when autoimmune toxicities occur.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.